Daiwa Securities raised its price target for Vertex Pharmaceuticals from $556 to $640.

Nov 10, 2026, 6:37 AM ETOpinionRead the original at marketscreener.com

Good for VRTX

Daiwa raised its share price target from $556 to $640, signaling a more favorable view of Vertex shares. The report gives no new sales or product results.

VRTX · Vertex Pharmaceuticals

AI read · Good for VRTX

The AI's read

That higher target reflects Daiwa's view, not a change in Vertex's sales, medicines, or reported results. It points to a more favorable view of the shares, but offers no new company results.

Get alerts for VRTX

Follow Vertex Pharmaceuticals (VRTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRTX

Free on the App Store and Google Play, or on the web.